Physician profile
Lainey Ortiz
NPI 1801352513
$7,458.85
in general payments reported to CMS, 2019-2025
33 companies · $2,281 in 2025
The $2,281 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,210 · 2022: $1,605 · 2023: $562 · 2024: $1,802 · 2025: $2,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,379 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,378.70 |
| Education | $265.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $724.48 | 2021-2025 | Opzelura, Opzelura |
| Abbvie INC. | $719.60 | 2021-2025 | |
| Amgen INC. | $682.64 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $489.21 | 2021-2025 | |
| Janssen Biotech, INC. | $463.41 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Regeneron Healthcare Solutions, INC. | $425.63 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $420.60 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $406.68 | 2021-2025 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $402.54 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $341.58 | 2021-2025 | |
| Dermavant Sciences, INC. | $300.73 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $295.94 | 2021-2025 | Nemluvio |
| Pfizer INC. | $290.49 | 2021-2025 | |
| Epi Health, LLC | $262.13 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $171.99 | 2022-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $160.07 | 2024-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $153.34 | 2022-2025 | Winlevi |
| Leo Pharma INC. | $115.93 | 2021-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $99.19 | 2021-2025 | Cabtreo |
| Paratek Pharmaceuticals, INC. | $74.82 | 2021-2025 | Nuzyra |
| Organon LLC | $70.99 | 2025 | Vtama, Hadlima, Nexplanon |
| Boston Scientific Corporation | $68.56 | 2021 | |
| Arcutis Biotherapeutics, INC. | $60.94 | 2024-2025 | Zoryve |
| Biofrontera INC. | $49.55 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.48 | 2024 | Spevigo |
| Kyowa Kirin, INC. | $34.84 | 2024 | Poteligeo |
| Almirall LLC | $34.01 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $24.25 | 2021 | |
| Strata Skin Sciences, INC. | $18.34 | 2024 | Xtrac |
| Journey Medical Corporation | $14.62 | 2021 | |
| Verrica Pharmaceuticals INC. | $14.17 | 2024 | Ycanth |
| Nabriva Therapeutics, Plc | $14.11 | 2022 | |
| Mission Pharmacal Company | $13.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lainey Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.